Scalper1 News
Bristol-Myers Squibb (BMY) stock was up nearly 3% in early trading on the stock market today, after late Tuesday’s news that the big pharma had stopped a trial of its cancer drug nivolumab early due to strong efficacy. The trial in question compared nivolumab with dacarbazine, a standard chemotherapy also known as DTIC, in previously untreated patients who had advanced melanoma. Bristol’s press release didn’t state exact numbers, but said the Scalper1 News
Scalper1 News